JPS6326760B2 - - Google Patents

Info

Publication number: JPS6326760B2
Authority: JP; Japan
Prior art keywords: complex salt; formula; manganese; copper; cobalt
Prior art date: 1981-05-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP8116381A

Other languages

English (en)

Japanese (ja)

Other versions

JPS57197284A (en

Inventor

Eiichi Suenaga

Kenji Miura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanwa Kagaku Kenkyusho Co Ltd

Original Assignee

Sanwa Kagaku Kenkyusho Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-05-29

Filing date

1981-05-29

Publication date

1988-05-31

1981-05-29 Application filed by Sanwa Kagaku Kenkyusho Co Ltd filed Critical Sanwa Kagaku Kenkyusho Co Ltd

1981-05-29 Priority to JP8116381A priority Critical patent/JPS57197284A/ja

1982-12-03 Publication of JPS57197284A publication Critical patent/JPS57197284A/ja

1988-05-31 Publication of JPS6326760B2 publication Critical patent/JPS6326760B2/ja

Status Granted legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 claims description 21
-1 Metal complex salt Chemical class 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 13
239000010949 copper Substances 0.000 claims description 9
206010003210 Arteriosclerosis Diseases 0.000 claims description 5
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
150000001450 anions Chemical class 0.000 claims description 5
208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
239000010941 cobalt Substances 0.000 claims description 5
229910017052 cobalt Inorganic materials 0.000 claims description 5
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 5
229910052802 copper Inorganic materials 0.000 claims description 5
229910052751 metal Inorganic materials 0.000 claims description 5
239000002184 metal Substances 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 4
239000011572 manganese Substances 0.000 claims description 4
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 4
229940124597 therapeutic agent Drugs 0.000 claims description 4
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 2
239000000460 chlorine Substances 0.000 claims 2
229910052748 manganese Inorganic materials 0.000 claims 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
210000001367 artery Anatomy 0.000 claims 1
229910052801 chlorine Inorganic materials 0.000 claims 1
239000002075 main ingredient Substances 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 14
239000000203 mixture Substances 0.000 description 9
239000000243 solution Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
239000013078 crystal Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
238000004364 calculation method Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000000921 elemental analysis Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000000034 method Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000001853 liver microsome Anatomy 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
206010060891 General symptom Diseases 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
229910000361 cobalt sulfate Inorganic materials 0.000 description 1
229940044175 cobalt sulfate Drugs 0.000 description 1
KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229940079721 copper chloride Drugs 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
229960000355 copper sulfate Drugs 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000005389 magnetism Effects 0.000 description 1
150000002696 manganese Chemical class 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
229940099607 manganese chloride Drugs 0.000 description 1
229940099596 manganese sulfate Drugs 0.000 description 1
235000007079 manganese sulphate Nutrition 0.000 description 1
239000011702 manganese sulphate Substances 0.000 description 1
SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229950009883 tocopheryl nicotinate Drugs 0.000 description 1

Landscapes

Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP8116381A 1981-05-29 1981-05-29 Alpha-tocopheryl nicotinate metal complex, its preparation, and remedy for arteriosclerosis comprising it as active ingredient Granted JPS57197284A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP8116381A JPS57197284A (en)	1981-05-29	1981-05-29	Alpha-tocopheryl nicotinate metal complex, its preparation, and remedy for arteriosclerosis comprising it as active ingredient

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP8116381A JPS57197284A (en)	1981-05-29	1981-05-29	Alpha-tocopheryl nicotinate metal complex, its preparation, and remedy for arteriosclerosis comprising it as active ingredient

Publications (2)

Publication Number	Publication Date
JPS57197284A JPS57197284A (en)	1982-12-03
JPS6326760B2 true JPS6326760B2 (de)	1988-05-31

Family

ID=13738781

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8116381A Granted JPS57197284A (en)	1981-05-29	1981-05-29	Alpha-tocopheryl nicotinate metal complex, its preparation, and remedy for arteriosclerosis comprising it as active ingredient

Country Status (1)

Country	Link
JP (1)	JPS57197284A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0347864A3 (de) *	1988-06-24	1992-04-01	Andries Johannes Cornelus Strydom	Antiatherosklerose-Mittel

1981
- 1981-05-29 JP JP8116381A patent/JPS57197284A/ja active Granted

Also Published As

Publication number	Publication date
JPS57197284A (en)	1982-12-03

Publication	Publication Date	Title
RU2621681C2 (ru)	2017-06-07	Способ
PT87788B (pt)	1992-10-30	Processo para a preparacao de derivados do 2,2-dimetil-3-cromanol que tem actividade anti-hipertensiva e anti-arritmica
JP2007302658A (ja)	2007-11-22	イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
JP2015508408A (ja)	2015-03-19	プロスタグランジン類似体の結晶型およびその製造方法と用途
JPH11507011A (ja)	1999-06-22	ラモトリジンの製造法
PT88718B (pt)	1992-12-31	Processo para a preparacao de derivados de 2,2-dimetil-cromeno
WO1997026242A1 (en)	1997-07-24	3-(bis-substituted-phenylmethylene)oxindole derivatives
US4748187A (en)	1988-05-31	Opioid peptide-degrading enzyme inhibitor with a germanium compound
HU176707B (en)	1981-04-28	Process for producing 14,15-dihydro-20,21-dinor-eburnamenine-14-ol-isomeres
KR100339115B1 (ko)	2002-11-07	결정성3-(4-헥실옥시-1,2,5-티아디아졸-3-일)-1,2,5,6-테트라하이드로-1-메틸피리딘(+)l-하이드로겐타르트레이트,이의제조방법및이를포함하는약제학적조성물
NO324365B1 (no)	2007-10-01	Metallkompleks, fremgangsmate for fremstilling derav, samt anvendelse derav i terapi
JPS6158449B2 (de)	1986-12-11
Golovnev et al.	2017	Polymeric lithium (I) diaquabarbiturate: Crystal structure
JP2716827B2 (ja)	1998-02-18	２４ｒ‐スキムノールならびにその製造および使用
JPS6041670B2 (ja)	1985-09-18	２，６−ジメチル−１，４−ジヒドロピリジン−３，５−ジカルボン酸エステルおよびその製造方法
JPH01207234A (ja)	1989-08-21	虚血性疾患治療剤および心筋保護剤
JPH0339513B2 (de)	1991-06-14
JPS6116272B2 (de)	1986-04-28
JPS5899490A (ja)	1983-06-13	リン酸アミド誘導体およびその製造方法ならびにそれを含有する医薬
SU982544A3 (ru)	1982-12-15	Способ получени 5,8-дигидро-5-этил-8-оксофуро (3,2в)-1,8-нафтиридин-7-карбоновой кислоты или ее соли
JPWO2007066557A1 (ja)	2009-05-14	ホスフィン遷移金属錯体、その製造方法およびそれを含有する抗癌剤
JPS6072892A (ja)	1985-04-24	スピロ（ベンゾフラン−アズアルカン）およびその製法
JPS6136266A (ja)	1986-02-20	イソキノリン誘導体およびそれを有効成分として含有する治療用組成物
JPS61249985A (ja)	1986-11-07	１，１２ｂ−ニ置換オクタヒドロインドロ〔２，３−ａ〕キノリジン誘導体
JPS61204198A (ja)	1986-09-10	２−オキサプレグナン化合物